Announcements
- Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
- Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
- Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
- Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
- Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
- Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
More ▼
Key statistics
As of last trade Verrica Pharmaceuticals Inc (1NE:FRA) traded at 8.23, -5.62% below its 52-week high of 8.72, set on May 14, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.23 |
---|---|
High | 8.23 |
Low | 8.23 |
Bid | 8.31 |
Offer | 8.48 |
Previous close | 7.95 |
Average volume | 0.00 |
---|---|
Shares outstanding | 42.42m |
Free float | 18.75m |
P/E (TTM) | -- |
Market cap | 383.90m USD |
EPS (TTM) | -1.75 USD |
Data delayed at least 15 minutes, as of May 23 2024 07:17 BST.
More ▼